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Abstract: Autoimmune diseases include 80 or more complex disorders characterized by 
self-reactive, pathologic immune responses in which genetic susceptibility is largely 
insufficient to determine disease onset. In September 2010, the National Institute of 
Environmental Health Sciences (NIEHS) organized an expert panel workshop to evaluate 
the role of environmental factors in autoimmune diseases, and the state of the science 
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regarding relevant mechanisms, animal models, and human studies. The objective of the 
workshop was to analyze the existing data to identify conclusions that could be drawn 
regarding environmental exposures and autoimmunity and to identify critical knowledge 
gaps and areas of uncertainty for future study. This consensus document summarizes key 
findings from published workshop monographs on areas in which “confident” and “likely” 
assessments were made, with recommendations for further research. Transcribed notes and 
slides were reviewed to synthesize an overview on exposure assessment and questions 
addressed by interdisciplinary panels. Critical advances in the field of autoimmune  
disease research have been made in the past decade. Collaborative translational and 
interdisciplinary research is needed to elucidate the role of environmental factors in 
autoimmune diseases. A focus on exposure assessment methodology is needed to improve 
the effectiveness of human studies, and more experimental studies are needed to focus on 
causal mechanisms underlying observed associations of environmental factors with 
autoimmune disease in humans.  
Keywords: National Institute of Environmental Health Sciences (U.S.);  
consensus; autoimmune diseases; mechanisms; environmental exposures; epidemiology; 
exposure assessment 
 
1. Introduction 
Autoimmune diseases result from a damaging immune response directed against the body’s own 
tissues. Of the 80 individual autoimmune diseases, common examples include rheumatoid arthritis 
(RA), Type 1 Diabetes (T1D), and the autoimmune thyroid diseases; others may be rarer, but as  
a group afflict 5%–9% of the U.S. population [1–5]. Chronic and incurable, these diseases constitute  
a major public health problem with high individual suffering and societal costs. The majority of 
autoimmune diseases disproportionately affect women with a few notable exceptions (e.g., Type 1 
diabetes) [5,6]. Some are more common or severe in different racial/ethnic populations (e.g., lupus in 
African Americans) and age-groups (e.g., Type 1 diabetes in children). The reasons for these 
differences and underlying cause(s) of autoimmune disorders remain largely unknown, but are likely  
to involve both genetic and environmental factors [2]. This is well illustrated by the concordance  
rates observed in monozygotic versus dizygotic twins, which differ significantly but remain in most 
instances are well below 50% [7]. 
Over the years, a number of trans-NIH committees and NIH-supported workshops have examined 
the role of the environment in the development of autoimmune disease [8–11]. In 2003, the NIEHS  
co-sponsored the “Environmental Factors in Autoimmune Disease” workshop (along with other  
NIH partners, the United States Environmental Protection Agency (EPA), and the American 
Autoimmune Related Diseases Assoc., Inc., Eastpointe, MI, USA), and in 2005 co-sponsored the 
“Workshop on Lupus & the Environment: Disease Development, Progression and Flares” [10,11]. 
These produced recommendations for research initiatives on the role of the environment in 
autoimmune disease. One specific recommendation was to facilitate interactions between specialties 
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and encourage multidisciplinary approaches to improve overall knowledge of the hazard, mechanisms, 
and outcomes associated with specific environmental exposures. 
To evaluate the state of the science and provide an opportunity for interactions between specialties, 
the NIEHS convened an “Expert Panel Workshop to Examine the Role of the Environment in the 
Development of Autoimmune Disease” on 7–8 September 2010. The goal was to bring together  
an interdisciplinary group of experts from the environmental health science and autoimmune  
research communities to review the literature and evaluate the state of the science, recommending  
productive directions for research on environmentally related autoimmune disease via the publication 
of a consensus statement. 
The workshop utilized a format implemented in previous expert panel meetings [12–14]. 
Participants were selected for three panels examining the role of the environment in the development 
of autoimmune disease: molecular mechanisms and receptor dynamics; animal models; and 
epidemiology/human studies. Each panel defined the areas for review and reported their findings, 
grouped by confidence levels: (1) “Based on existing evidence we are confident of the following…”; 
and (2) “We consider the following to be likely but require confirmation…”. The panels were asked  
to identify key knowledge gaps and broad themes for future research. Each group determined the  
scope of environmental factors they would consider, but all included chemical, physical, biological 
exposures. A fourth panel was tasked with addressing issues in exposure assessment, a topic of 
importance to the advancement of human studies. 
During the second half of the workshop, four trans-disciplinary panels were formed consisting of 
members from each of the original review panels. Each panel discussed a common set of over-arching 
question using the same framework as the initial reviews and reported the findings according to 
confidence level with summary recommendations for broad themes for future investigations. 
In this workshop report and consensus document, we summarize the individual panel reviews on 
mechanisms, animal models, and human studies, published elsewhere in full [15–17]. Because of the 
volume of literature reviewed, citations here are limited to key publications and examples. This report 
also summarizes findings from the panel on human exposure assessment and the interdisciplinary 
panel discussions. 
2. Workshop Summaries 
2.1. Mechanisms 
The specific mechanisms leading to autoimmune diseases and the effects of environmental 
exposures on those mechanisms remain largely unknown. A variety of experimental studies are 
beginning to identify mechanisms by which environmental agents may induce or enable tolerance 
breakdown and/or autoimmune disease. Focusing on environmental exposure-based autoimmunity, the 
panel examined six major sub-topics summarized in Table 1 [15] including: effects on innate immunity 
such as Toll-like receptor (TLR) activation by xenobiotics; adjuvant effects and inflammatory 
responses; B cell activation; direct effect impairing the immune function, such as T-helper 17 (Th17) 
cells T regulatory (Treg) cells; and modifications of self-antigens. 
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Table 1. Panel findings on mechanisms involved in the role of environmental factors and development of autoimmune disease. 
We Are Confident of the Following We Consider the Following Likely,  
but Requiring Confirmation  
Broad Themes to Be Pursued in  
Future Investigations 
B cells    
Dysfunctions of B cell tolerance checkpoints are directly 
correlated with autoimmune disease in murine models;  
B cells modulate autoimmunity positively and negatively as 
secretors of antibodies and inflammatory cytokines, as 
antigen presenting cells to autoreactive T cells, and secretors 
of anti-inflammatory cytokines such as IL-10;  
Follicular B cells (B2) are a major source of autoreactive 
pathogenic antibodies;  
B cells secreting pathogenic autoantibodies can emerge 
when somatic hypermutation occurs outside of  
germinal centers;  
Sex hormones like estrogen and prolactin can differentially 
activate autoreactive B cell populations from different 
subsets (e.g., B2). 
B1 cells and marginal zone B cells can modulate 
autoimmunity by exacerbating it through 
secretion of autoreactive antibodies and/or by 
down-modulating it through secretion of  
anti-inflammatory cytokines;  
B10 cells appear to exclusively secrete IL-10 
may be functionally specialized to carry out  
a negative regulatory role in inflammation  
and autoimmunity. 
The roles of B1 and marginal zone B cells  
in autoimmunity;  
The role of the recently discovered B10 cell 
population in autoimmunity;  
The survival/apoptotic pathways that when 
dysregulated lead to expansion and survival of 
autoreactive B cells (such as the BAFF/BlyS 
receptor system and CD40);  
Tolerance checkpoint mechanisms regulating the 
formation of high affinity autoreactive B2 cells 
both in and outside the germinal center;  
Environmental agents with the potential to disrupt  
B cell function. 
T-helper 17 (TH17) cells   
Dysregulated Th17 cell activity can lead to pathology, as in 
chronic inflammatory diseases such as asthma or 
inflammatory bowel disease;  
Th17 cells are involved in multiple sclerosis (MS), 
rheumatoid arthritis (RA), Crohn’s disease and psoriasis, 
where they seem to be involved in disease development  
and relapse. 
Smoking is an important risk factor for RA; and 
nicotine exerts effects via Th17 cells;  
Aryl-hydrocarbon Receptor (AhR) binding by 
aromatic hydrocarbons and non-halogenated 
polycyclic aromatic hydrocarbons favors 
differentiation of Th17 cells and can  
exacerbate autoimmunity. 
The involvement of environmental agents and 
exacerbation of autoimmune disease through 
Th17 cells;  
Therapeutic modulation of Th17 cells. 
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Table 1. Cont. 
We Are Confident of the Following We Consider the Following Likely,  
but Requiring Confirmation  
Broad Themes to Be Pursued in  
Future Investigations 
Innate Immunity   
The interaction between xenobiotics and Toll-like receptor 
(TLR) is a major mechanism involved in the interaction of 
environmental factors with autoimmunity development;  
Innate immune activation via TLR predisposes to  
toxic-induced inflammation;  
Adjuvants activate both innate and adaptive immunity, 
inducing release of chemokines and  
inflammatory cytokines;  
Immunization must be accompanied by a strong adjuvant, 
such as complete Freunds adjuvant, including the 
mycobacterium component. Incomplete Freund adjuvant 
results in production of antibodies, but without occurrence 
of autoimmune diseases. 
Altered innate immune responses and 
dysregulated TLR signaling are a key step in 
triggering autoimmune diseases, as in  
virus-induced animal models of type I diabetes;  
TLR activation in macrophages may predispose 
cells to toxin-induced inflammatory  
cytokine production;  
Active infection or microbial products of 
infection can provide the adjuvant effect 
necessary for the induction of many  
autoimmune disorders. 
Allergenicity, functional mimicry of 
environmental contaminants and 
physical/chemical elements resembling  
TLR ligands;  
Dysregulation of the regulatory B cell  
(IL-10 producing, CD5+ B cells) through 
modulation of TLR signaling;  
Molecular motifs of adjuvants and their 
physiological receptors that are associated with 
clinical manifestation of autoimmunity;  
Genomic predisposition to innate immunity 
dysfunctions. 
T-regulatory (Treg) cells   
Quantitative and qualitative Treg changes contribute to a 
breakdown in tolerance;  
The AhR ligand dioxin 2,4,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) induces immunosuppressive T cells expressing 
specific Treg markers;  
AhR ligands also affect skewing of the T cell repertoire 
towards Treg cells indirectly via antigen presenting cells;  
TCDD induces indoleamine 2,3-dioxygenase (IDO) 
transcription to skew the T cell repertoire towards  
FoxP3+ Tregs;  
Activation of peroxisome proliferator-activated receptor 
gamma (PPARγ) promotes Treg induction from naïve cells. 
Most studies suggest that AhR activation in  
T cells or in antigen presenting cells may 
increase Treg production and therefore decrease 
autoimmunity, but the opposite outcome is also 
likely and possibly ligand-specific;  
Context-specific activation of the AhR by 
specific ligands may result in either increased or 
decreased Treg activity;  
Sex hormones play an important role in Treg 
development and may underlie female 
predominance of autoimmune diseases. 
Specific chemical, infectious, or physical agents 
capable of modulating Tregs;  
Environmental modulators of AhR stimulation;  
Mechanisms of sex-specific Treg changes. 
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Table 1. Cont. 
We Are Confident of the Following We Consider the Following Likely,  
but Requiring Confirmation  
Broad Themes to Be Pursued in  
Future Investigations 
Modification of self-antigens   
The majority of human proteins undergo  
post-tranlational modification (PTM) and these 
modifications or lack thereof may lead to  
tolerance breakdown;  
PTM may explain the tissue specificity of  
autoimmune diseases;  
MS pathogenesis includes PTM that increase the complexity 
of myelin proteins through the autoimmune response or 
neurodegenerative processes;  
In RA, citrullination is an apoptotic PTM that seems to be 
helpful in opening protein conformation and favoring 
cleavage processes;  
In PBC, cholangiocytes do not covalently link glutathione to 
lysine-lipoyl groups during apoptosis leading to 
accumulation and exposure to potentially self-reactive 
antigens, accounting for bile duct specific pathology. 
Multiple self-protein modifications 
(phosphorylation, glycosylation, acetylation, 
deamidation) can lead to either T or B cell 
responses to self-antigens;  
Serum autoantibodies to modified self antigens 
may bind either modified or unmodified forms 
and thus be crucial to effector immune reaction 
in target tissues;  
Mercury-induced cell death results in formation 
of a unique and more immunogenic 19 kDa 
cleavage fragment of fibrillarin. 
Mechanisms by which citrullination and 
glutathionylation lead to tolerance breakdown in 
susceptible individuals;  
The role of glucosylation in MS and other  
autoimmune diseases;  
Experimental models to prove that autoantigens 
can be modified to increase their immunogenicity;  
Technologies to reverse or induce PTM in animal 
models of autoimmunity. 
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Table 1. Cont. 
We Are Confident of the Following We Consider the Following Likely,  
but Requiring Confirmation  
Broad Themes to Be Pursued in  
Future Investigations 
Modification of DNA methylation   
DNA methylation profiles are associated with 
environmental factors including prenatal tobacco smoke, 
alcohol, and environmental pollutants;  
The importance of DNA methylation in regulating immune 
function is suggested by two rare congenital diseases, 
Silver-Russel and Beckwith-Wiedemann syndromes;  
Changes in DNA methylation in specific peripheral immune 
cell types are associated with autoimmune diseases. 
Phenotypic differences are increased with age in 
twins in a trend coined as “epigenetic drift”, due 
to different environmental exposures, and may 
explain late-onset autoimmunity;  
Specific impairments in epigenetic regulation in 
immune cells may be responsible for  
immune-tolerance breakdown through  
hypo-methylation of genes or involvement of 
transcription repressors;  
Recent genome-wide association studies 
demonstrate that genomics significantly 
predispose to systemic lupus erythematosus 
(SLE) onset, but experimental studies indicate 
that epigenetic mechanisms, especially impaired 
T and B cell DNA methylation, may be one of 
these factors. 
The functional effects in vivo of DNA methylation 
changes under different environmental and 
genomic conditions;  
The development of new therapeutic molecules 
capable of preventing or counteracting DNA 
methylation changes in a cell-specific manner;  
The DNA methylation changes in the target cells 
and not only in the rapidly accessible effector 
immune cells. 
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2.1.1. Effects on Innate Immunity 
Two major related mechanisms within innate immunity were discussed: Toll-like receptor (TLR) 
activation, and the role of adjuvants. The Toll-like receptors (TLRs) are pattern recognition receptors 
that play a key role in the effectiveness and function of the innate immune system. The panel was 
confident that TLR activation and signaling is a major mechanism linking environmental factors to 
development of autoimmunity. TLR deficiency impacts both disease severity and autoantibody profiles 
in pristane-induced autoimmunity [18]. Moreover, TLR-related pathways are likely to play a role in 
virally-induced animal models of autoimmune disease (e.g., Type 1 diabetes), and active infections or 
microbial exposures may provide the necessary adjuvant effect for the induction of many autoimmune 
diseases. Recommendations for further research included investigation of environmental factors and 
TLR activation, and TLR-related effects on regulatory B cells [19–21]. 
Adjuvants are agents that non-specifically stimulate the immune system without direct antigenic 
effects, including TLR-mediated effects on innate immune response and factors that modulate  
the adaptive immune response. The panel concluded that adjuvants (e.g., complete Freund’s) are  
important in the development of autoimmune disease. Further research is needed to characterize  
molecular aspects of adjuvants and receptors involved in autoimmune diseases, and on genetic risk 
factors that may modify autoimmune responses to environmental adjuvants and triggers of the innate  
immune response [11,22,23]. 
2.1.2. B Cell Activation 
One of the two major cell types in the adaptive immune response, B cells secrete pathogenic  
auto-antibodies and can also present antigens to auto-reactive T cells. A breakdown in central 
tolerance (in the bone marrow) is a major contributor to autoimmunity in many experimental models. 
Determining the contributions of B cell subtypes in autoimmune disease and the role of environmental 
factors in biasing their activation is critical. The panel reported a high degree of confidence in the role 
of follicular B cells and the influence of sex hormones (e.g., estrogens) via this mechanism, and that 
research is needed to identify effects of environmental exposures on B cell development and function, 
e.g., environmental estrogens [24–27]. 
2.1.3. T-Helper 17 Cells 
T-helper 17 (Th17) cells, an interleukin 17 (IL17)-producing subset of T-helper cells, play an 
important role in the adaptive immune response and mechanisms leading to autoimmunity and  
chronic inflammation. The panel was confident that dysregulation of Th17 cells contributes to chronic 
inflammatory pathology, and that Th17 cells are involved in development and relapse of several 
autoimmune diseases [28,29]. 
Increasing evidence suggests that xenobiotics, allergens and micronutrients can influence Th17 cells 
at multiple levels. For example, smoking, a risk factor for RA and other autoimmune diseases, exerts 
effects on Th17 cells through nicotine exposure. Aromatic hydrocarbons and non-halogenated 
polycyclic aromatic hydrocarbons also induce differentiation of Th17 cells through binding at the  
Aryl hydrocarbon Receptor (AhR), exacerbating autoimmunity. Given the important role of Th17 cells 
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on development and exacerbation of autoimmunity, more research is needed on the effects of 
environmental exposures on Th17 cells [30–32]. 
2.1.4. T Regulatory (Treg) Cells 
T regulatory (Treg) cells play a key role in the maintenance of immune tolerance, and can dampen 
or suppress activation of the immune system. Experimental studies demonstrate a number of 
mechanisms through which environmental agents may affect Treg induction or function. The panel 
was confident that changes in Treg cells play a role in loss of tolerance for self-antigens. Strong 
evidence supports 2,4,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induction of suppressive T cells with 
Treg markers, along with mechanisms involving antigen-presentation, through which AhR ligands 
skew the T cell repertoire towards Treg production [33–35]. The peroxisome proliferator-activated 
receptor gamma (PPARγ) receptor is activated by a wide variety of environmental chemicals  
(e.g., phthalate esters), promoting Treg induction [36,37]. 
Confirmation is needed that the context-specific activation of the AhR by specific ligands  
may result in either increased or decreased Treg activity. Sex-hormones are likely to regulate  
Treg development, and may underlie the female predominance of most autoimmune diseases. The 
panel concluded that studies should focus on environmental factors capable of modulating Treg and  
AhR activity and also consider the role of chemical mixtures and direct stressors, such as ultraviolet  
(UV)-light [35,38–40]. 
2.1.5. Modification of Self-Antigens 
Post-translational modification (PTM) is the chemical modification of a protein following its 
synthesis, e.g., methylation, phosphorylation, acetylation, lipidation, or glycosylation, occurring on 
50% to 90% of proteins in the human body. An environmental exposure may alter PTM, affecting 
immunogenicity of self-proteins and triggering an autoimmune response. PTM may explain tissue 
specificity of some autoimmune diseases. For example, PTM increases complexity of myelin  
proteins through autoimmune or neurodegenerative processes in MS. Conversely, lack of PTM during 
apoptosis alters protein degradation and leads to accumulation of self-reactive antigens related to bile 
duct specific pathology of primary biliary cirrhosis (PBC) [41,42]. 
Confirmation is needed that multiple types of environmentally-induced PTM may lead to B and  
T cell reactivity to self-antigens, and that self-reactive antibodies react to both modified and unmodified 
forms of antigen. One example is the binding of mercury to fibrillarin to create a modified self-antigen 
and the generation of a new cleavage fragment due to proteolysis following mercury-induced cell 
death. Research is also needed on mechanisms by which citrullination (e.g., linking smoking to RA) 
leads to loss of self-tolerance and studies of PTM biomarkers across the natural history of autoimmune 
diseases [43–47]. 
2.1.6. Modifications of DNA Methylation 
The field of epigenetics examines the regulation of the genome through modifying mechanisms  
not involving changes in the nucleotide sequence itself, such as DNA methylation and histone 
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acetylation. Environmental factors can affect epigenetic gene regulation, and so understanding  
the role of epigenetic modifications in the development of autoimmunity is an important topic for 
future study. The panel confidently noted the association of DNA methylation profiles with 
environmental exposures, including prenatal tobacco smoke, alcohol use, and environmental pollutants 
(i.e., particulate matter). 
Confirmation is needed that ageing-related phenotypic changes arise due to exposures over the 
lifetime, contributing to development of autoimmune diseases later in life. Studies are needed to show 
whether loss of tolerance is related to specific exposure-associated impairments in regulation of epigenetic 
processes and confirming impaired methylation of B and T cell DNA in relation to systemic lupus 
erythematosus (SLE) risk. Recommendations include research on the in vivo effects of DNA methylation 
under different environmental conditions and target tissue differences in DNA methylation associated 
with autoimmune diseases [7,48].  
2.2. Animal Models 
Animal models have been used extensively in the study of autoimmune disease and the role of 
environmental exposures. The panel focused their attention on studies of non-therapeutic chemical, 
biological, and physical factors associated with autoimmune outcomes as summarized in Table 2 [17]. 
A high level of confidence was reached if multiple studies from different laboratories confirmed the 
same findings. For findings considered likely and requiring further confirmation, there needed to be 
significant support, including multiple studies from a single laboratory, or repetition of some but not 
all findings in multiple laboratories. 
The panel noted that autoimmune responses to chemical factors are species and strain-specific. 
Autoimmune animal models (predominately rats and mice) are typically genetically manipulated or 
inbred strains that spontaneously develop disease or autoimmunity induced by immunization with 
specific antigens. Some studies of environmental factors in autoimmunity involve the induction  
of autoimmune diseases or autoimmunity in non-susceptible, inbred strains. Due to the genetic 
complexity of disease susceptibility, autoimmune effects may not be observed. Thus, studies may also 
investigate environmental effects on models of spontaneous autoimmune disease, in which case the 
effects of exposure may include exacerbation or acceleration of disease expression. Because of the 
great depth of the literature in this area, the published review on animal models and autoimmune 
diseases was limited in scope [17]; an additional white paper on the full workshop review session is 
available by request. 
Studies provided conclusive evidence that forms of inorganic mercury (HgCl2, vapor, amalgam) can 
induce systemic autoimmune disease in rats (transient) and mice [49], and exacerbate or accelerate 
systemic disease in lupus-prone mice [50]. Several mineral oil components and other hydrocarbons  
can induce inflammatory arthritis in rats [51]; and one component, 2,5,10,14-tetramethylpentadecane 
(TMPD or pristine) induces lupus-like disease and inflammatory arthritis in some strains of mice [52]. 
With a high degree of confidence, the panel also noted a role for specific pathogens (i.e., Streptococcal 
group A, Coxsackie B virus) and exacerbation of autoimmune thyroiditis by iodine in genetically 
predisposed animal models.  
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Table 2. Panel findings studies of animal models in the role of environmental factors and development of autoimmune disease. 
We Are Confident of the Following We Consider the Following Likely,  
but Requiring Confirmation
Broad Themes to Be Pursued in  
Future Investigations
Forms of inorganic mercury (HgCl2, vapor, 
amalgam) induce systemic autoimmune disease in 
rats (transient) and mice, and exacerbates systemic 
autoimmune disease in lupus-prone mice;  
Several mineral oil components and certain other 
hydrocarbons can induced an acute inflammatory 
arthritis in some rat strains;  
The mineral oil component  
2,6,10,14-tetramethylpentadecane (TMPD or 
pristane) induces lupus-like disease and 
inflammatory arthritis in several strains of mice;  
For a limited number of pathogens there is a clear 
association with development of  
autoimmune diseases;  
Excess iodine increases the incidence of 
autoimmune thyroiditis in genetically predisposed 
animal models. 
Gold causes (transient) nephropathy in rats. Gold and 
silver cause autoimmune responses, but not autoimmune 
disease, in mice; but the ability of silver and gold to 
exacerbate spontaneous autoimmune disease  
requires study;  
Silica exacerbates autoimmune disease but more studies 
are needed using more species/strains and  
a wider range of doses and exposure routes;  
Trichloroethylene (TCE) exacerbates systemic 
autoimmunity although responses are often limited and 
transient. Studies of autoimmune liver disease are  
needed with additional species/strains and in 
developmental studies;  
TCDD exposure during fetal or early neonatal 
development may promote autoimmunity;  
Organochlorine pesticides may enhance lupus-like disease 
in a predisposed mouse strain;  
Sunlight/ultraviolet (UV) light exposure exacerbates lupus 
in genetically prone mice. 
Studies should be “shaped by what is observed in 
humans, not by what is possible in mice” [53];  
Studies should not be restricted to a “gold standard” 
animal model. Multiple models should be 
investigated to reflect human genetic heterogeneity;  
When using spontaneous disease models it is 
important to consider whether environmental 
exposures directly impacts idiopathic 
autoimmunity, or reflects environmental  
factor-specific autoimmunity;  
More studies on the effects of environmental factor 
exposure on expression of autoimmunity during 
different stages of life (gestational to adulthood)  
are needed. 
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The panel considered a wide range of other associations to be likely, but needing confirmation. 
Examples include some heavy metals (gold and silver), though more studies are needed of other metals 
(organic mercury, cadmium, lead, and arsenic) to confirm observed effects. Silica exacerbates 
autoimmune disease in lupus models, but studies are needed in different species/strains and across  
a wider range of exposure routes and doses. Evidence is suggestive that trichloroethylene (TCE) can 
exacerbate systemic autoimmunity in a limited or transient manner, and UV radiation/sunlight is likely 
to exacerbate lupus in genetically prone mice. Developmental exposures (fetal/neonatal) to TCDD  
may promote systemic autoimmunity, supporting the idea that early exposures may influence the 
developing immune system and subsequent development of disease. Findings that organochlorine 
pesticides (e.g., dichlorodiphenyltrichloroethane [DDT]) enhance autoimmune disease in a susceptible 
mouse model also require confirmation. 
The panel noted several themes for future use of animal models to study environmental 
autoimmunity and disease. Above all, it was recommended that findings in animal models should not 
be the only driving force for human studies, which should be “shaped by what is observed in humans, 
not by what is possible in mice”. A single mouse strain cannot encompass the genetic heterogeneity in 
human populations, so studies should not be limited to “gold standard” animal models. Rather, the 
effects of environmental exposures should be tested on multiple models, and if necessary, humanized 
models. Exposure effects should be examined during all stages of life, from gestation to adulthood. 
When using spontaneous autoimmune models, studies should consider whether exposures exacerbate 
or accelerate idiopathic autoimmunity or induce more specific “environmentally-associated” forms of 
autoimmunity. The panel also recommended specific improvements to animal studies, including use  
of disease markers from easily obtained biological fluids (e.g., blood) to enhance comparisons with 
human studies. 
2.3. Epidemiology/Human Studies 
Findings of the epidemiology/human studies review are summarized in Table 3 [16]. The panel 
restricted their focus to peer-reviewed studies published in the last 30 years using defined Medline 
searches of the primary literature. Meta-analyses were examined with respect to study identification, 
inclusion and exclusion criteria, and the methods used to abstract and derive summary estimates. When 
the design and analysis methodology was deemed acceptable, the study estimate was used to summarize 
evidence through the period covered by that review; additional studies published subsequent to the  
meta-analysis were also reviewed. 
Diseases of focus included: Crohn’s disease (CD), gluten-sensitive enteropathy (GSE, celiac 
disease), Graves’ disease (GD), Hashimoto’s thyroiditis (HT), idiopathic inflammatory myopathies 
(IIM), multiple sclerosis (MS), primary biliary cirrhosis (PBC), rheumatoid arthritis (RA), systemic 
lupus erythematosus (SLE), systemic sclerosis (SSc), type 1 diabetes (T1D), and ulcerative colitis 
(UC). Additional diseases were examined if a substantial literature existed for a particular exposure 
e.g., eosinophilia myalgia syndrome [54]. Exposures were grouped in three broad classes: chemicals, 
physical factors, and biologic agents. 
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Table 3. Panel findings on human studies on the role of environmental factors and development of autoimmune disease. 
We Are Confident of the Following We Consider the Following Likely, 
but Requiring Confirmation  
Broad Themes to Be Pursued in Future Investigations 
Chemicals    
Crystalline silica (quartz) contributes to development of 
several systemic autoimmune diseases, including RA, 
systemic sclerosis (SSc), SLE and anti-neutrophil 
cytoplasmic antibody  
(ANCA)-related vasculitis.  
Solvents contribute to development SSc.  
Smoking contributes to development of  
anti-citrullinated protein antibody (ACPA)-positive and 
anti-rheumatoid factor.  
(RF)-positive RA (with an interaction with the shared 
eptiope genetic susceptibility factor).  
Solvents contribute to development  
of MS.  
Smoking contributes to development 
of seronegative RA, MS, SLE, 
Hashimoto’s thyroiditis (HT), 
Graves’ disease (GD) and Crohn’s 
disease (CD).  
Current smoking protects against 
development of ulcerative  
colitis (UC). 
There is insufficient evidence on the role of metals, including 
those associated with animal models of autoimmunity,  
e.g., mercury.  
The identification of single causal agents within groups of 
exposures is needed (e.g., specific solvents or pesticides 
contributing to increased risk for the group).  
Studies are needed on plasticizers (e.g., phthalates and bisphenol 
A), some of which may be endocrine or immune disruptors, and 
have been associated with other immune mediated diseases.  
There is insufficient evidence on the role of cosmetics in 
autoimmune diseases. 
Physical factors   
An inverse association exists between increased 
ultraviolet radiation exposure and risk of developing MS. 
Ionizing radiation contributes to 
development of HT and GD. 
There is insufficient evidence on a possible protective role of 
ultraviolet radiation on type 1 diabetes (T1D).  
Prospective data are needed on sun exposure as a risk factor for 
SLE (prior to early clinical symptoms) and dermatomyositis. 
Biologic agents   
Ingestion of gluten contributes to development of  
gluten-sensitive enteropathy (GSE).  
Ingestion of certain lots of L-Tryptophan contributes to 
development of eosinophilia myalgia syndrome.  
Dietary intake of 1,2-di-oleyl ester (DEPAP)- and oleic 
anilide-contaminated rapeseed oil contributes to 
development of toxic oil syndrome. 
Epstein-Barr virus (EBV) infection 
contributes to MS development.  
Early introduction of complex foods 
contributes to development of T1D 
and GSE.  
Low dietary vitamin D intake and 
blood levels contribute to 
development of MS. 
Studies are needed on MS and vitamin D in racial/ethnic groups 
with darker skin (associated with UV-associated vitamin D 
deficiency), and examining dose-effects.  
Prospective data are needed on vitamin D and other  
autoimmune diseases.  
Additional studies are needed on associations of food chemicals, 
dyes, or additives.  
Prospective studies are needed on nitrates/nitrosamines and T1D. 
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A “confident” association was based on evidence from multiple studies in different populations 
using different designs; robust evidence of an overall association (i.e., high magnitude risks or based 
on high quality or established exposure assessment methods); a dose-response relationship, or effect 
differences by disease subtype or genetic factors supporting biologic plausibility. “Likely” associations 
were based on similar body of research, but missing key evidence, such as a temporal relationship, less 
consistent results, or fewer studies. 
2.3.1. Chemical Factors 
The panel was confident that crystalline silica exposure contributes to development of several 
systemic autoimmune diseases, including RA, SSc, SLE, and anti-neutrophil-cytoplasmic antibody 
(ANCA)-associated vasculitis [55,56]. Evidence also supports an association of solvent exposure  
(in general) and development of SSc [57]. The panel was confident that smoking contributes to  
anti-citrullinated peptide antibody (ANCA) and anti-rheumatoid factor (RF)-positive RA, interacting 
with the shared epitope genetic risk factor [58,59]. 
Evidence also suggests smoking is likely to play a role in development of seronegative RA, MS, 
SLE, HT, GD, and CD, while protecting against UC [60,61]. Research needs varied by disease type; 
findings are inconsistent on the relation of smoking with MS and SLE. General solvent exposure  
may also contribute to development of MS, but more research is needed using improved exposure 
assessment methods. Major research gaps include studies of metals associated with autoimmunity  
in animal models and identification of specific causal agents within general groups of exposures  
(e.g., pesticides or solvents). Based on their endocrine and immune-disrupting qualities, the panel 
recommended studies of plasticizers in development of autoimmune diseases.  
2.3.2. Physical Factors 
The panel was confident in the inverse association of higher UV exposure and risk of MS [62]. 
Ionizing radiation is likely to contribute to development of autoimmune thyroid diseases (HT and GD), 
though several limitations contribute to a degree of uncertainty. These include studies of medical 
radiation therapy that did not distinguish HT from general hypothyroidism, and inconsistency in 
findings from nuclear testing fallout and accidental radiation contamination. Research gaps include the 
role of UV exposure as a protective factor against T1D and as a risk factor for dermatomyositis and 
SLE, with prospectively collected data and attention given to the period prior to potential clinical 
symptoms related to sun sensitivity. 
2.3.3. Biological Factors 
The panel was confident about the role of gluten in the development of GSE [63]. Strong evidence 
supports a role of specific environmental exposures in eosinophilia myalgia syndrome [54] and toxic 
oil syndrome [64]. 
It was also deemed likely that Epstein-Barr virus (EBV) infection contributes to development of 
MS, and that early introduction of complex (e.g., solid) foods contributes to development of T1D and 
GSE. The panel noted that MS may be associated with lower vitamin D intake and blood levels, but 
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research was recommended in non-Caucasian populations at higher risk of UV-related vitamin D 
deficiency, and studies of dose-effects. Prospective studies on vitamin D and other autoimmune 
diseases were also recommended. A research gap was noted on the role of food additives, dyes, and 
chemicals, and prospective studies on the role of nitrates and nitrosamines in T1D. 
Broad recommendations for future epidemiologic research included studies of multiple exposures 
and chemical mixtures, reflecting the real life complexity of human exposures. More studies are 
needed on exposure-related risks within specific disease phenotypes and in the context of genetic risk 
factors, such as the association of smoking with RA in the context of anti-citrullinated peptide 
antibody positivity and the shared epitope. Research needs also include defining critical windows in 
the timing of exposures and latencies relative to developmental stage, understanding dose-response 
relationships, and identifying mechanisms. 
2.4. Exposure Assessment in Human Studies 
Addressing a unique need recognized by the epidemiologic and clinical research community,  
the workshop also included a focus group on exposure assessment, bringing together experts in 
epidemiologic methods and exposure measurement technologies. Most autoimmune diseases are 
chronic and the relevant timing of exposures is not well established. Because most of the diseases are 
individually rare, retrospective case-control studies are often the most efficient design, with assessment 
methods based on questionnaires, relying on self-report and recall. The accuracy of internal dose 
estimates may be improved using exposure biomarkers, such as serum pesticides or metals; however, 
many exposures (e.g., silica) do not have easily accessible biomarkers, and for others (e.g., pesticides 
or metals), current biomarker levels may misclassify exposures during relevant time-periods of disease 
initiation or progression. 
The ability to identify environmental risk factors for autoimmune diseases depends heavily on the 
availability of rigorous exposure assessment methods that can be applied in different populations  
and allow comparisons across studies. Standardized questionnaires, such as those offered by the  
PhenX Toolkit [65], may address this need for some exposures, such as smoking. But studies 
identifying or confirming risk factors for autoimmune diseases often require greater detail on specific 
agents, such as solvents or pesticides, which vary by disease. Assessment methods may also need to be 
tailored to specific populations or settings, such as the methods used to assess occupational silica 
exposure in women in rural versus urban settings [66,67]. A life-course perspective is also critical, 
given the general lack of knowledge on the relevant time-windows of exposures in human studies and 
the well-established influence of developmental exposures on the immune system. 
New technologies in exposure measurement are being developed with potential applications in 
autoimmune disease research. Personal measurement technologies may have limited usefulness in 
assessing exposures years or decades prior to disease onset, but may help validate questionnaires on 
current or recent exposures or in long-term follow-up studies. Studies are also using new technologies 
to link geographic exposures with autoimmune disease studies, for example: air pollution and RA [68], 
UV radiation and dermatomyositis [69]. 
The panel recommended an integrated approach to improve exposure assessment in human 
autoimmune disease research. While adequate tools may exist to assess some relevant exposures  
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(e.g., smoking, silica), they are not widely accessible to researchers and their use typically requires 
collaboration with experts in assessment methodology. The application of new technologies may improve 
the accuracy and efficiency of existing methods, for example, using measurement data to validate 
questionnaires. Analytic methods that utilize complex data resources to model past exposures [70–72],  
or simultaneously take into account multiple exposures (e.g., Exposure-wide association studies; 
EWAS, [73,74]), will be important resources for future studies. Applications of information technologies 
are also needed to create useful databases incorporating biomarkers, questionnaires, measurement 
studies, and data analysis guidelines for autoimmune researchers. These investments require a focus on 
the “big picture” and integration across disciplines, with research and infrastructure development that 
requires support and cooperation across multiple agencies conducting public health and scientific 
research, such as the Centers for Disease Control and Prevention, National Institutes of Health, 
Environmental Protection Agency and National Science Foundation. 
Specific recommendations for advancing exposure assessment in environmental autoimmune 
diseases research include: (1) improving sensitivity, specificity, and dose estimates for established risk 
factors for one or more specific autoimmune diseases (i.e., silica, solvents, UV radiation); (2) a focus 
on disease risk in high exposure groups (occupational, military, and other risk populations);  
(3) consideration of highly prevalent or emerging “new” exposures (e.g., obesity, phthalates);  
and (4) prospective exposure assessment in susceptible populations (e.g., family members autoimmune 
disease patients, women). Resources are also needed to guide clinicians in the collection and 
interpretation of environmental exposure data [75]. Information collected in clinical settings is often 
limited to smoking and current occupation. In order to target specific exposures (e.g., silica or 
solvents), clinically applicable questionnaires are need to integrate across a wide variety of industries 
and occupations, including past as well as ongoing exposures. 
2.5. Transdisciplinary Breakout Panels 
Integrated responses from the four transdisciplinary breakout panels identified a range of specific 
needs and opportunities advancing research in environmental autoimmunity. 
Topic 1—Do animal models recapitulate disease observed in humans following exposure? 
In the majority of examples animal models do not entirely mimic human autoimmune diseases. 
Across the range of 80+ autoimmune diseases, most have complex etiologies, while animal models  
are designed to minimize complexity to foster an understanding of mechanisms. Exceptions in  
which animal models recapitulate features associated with environmental autoimmunity/disease in 
humans include pristane-induced lupus, toxic oil syndrome, Coxsackie virus-induced myocarditis, and  
L-tryptophan-associated eosinophilia–myalgia syndrome (EMS). The (NZBxNZW)F1 model also 
recapitulates human SLE (with central nervous system (CNS) involvement, vasculitis, dermatitis), and 
models of ultraviolet B (UVB) exposure and SLE exacerbation correspond well with the common 
clinical perception of flares and lupus. In these cases, however, the complexity of the animal model 
approaches that of the human disease, making a mechanistic understanding more difficult to achieve. 
A number of models support human data on environmental risk factors for autoimmune diseases, but 
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need further development and characterization, including models of TCE-induced autoimmunity 
designed to investigate the relationship of solvents and autoimmune diseases, including SSc. 
In several instances, animal models of environmentally induced autoimmune need to be promoted 
when there are good epidemiological data supporting an association. A prime example is that of silica 
and silicate exposures, which have been associated with multiple autoimmune diseases in humans. 
These findings are corroborated by relatively few studies in animal models, and so more work is 
recommended, particularly for the inhalation route of exposure. Other examples include studies of 
smoking effects on MS, and early dietary exposures and diabetes. (At the same time, epidemiological 
studies should also be promoted when good mechanistic data exists based on animal studies (such as 
mercury-induced SLE-like disease, and effects of mercury and other heavy metals associated  
with exacerbations)). Panel discussions highlighted a need for genetically diverse animal models of 
autoimmunity to reflect the heterogeneity of human populations and for studies of gene-environment 
interactions. Models are also needed that reflect relevant doses and exposure mixtures, and that mimic 
the sex differences often seen in human autoimmunity. 
Topic 2—Do exposures associated with autoimmune disease in vitro and in animal models have 
relevance to exposures in human populations? 
Although exposure levels in human studies of autoimmunity are often unclear, animal models 
generally use higher doses to shorten experimental periods or reveal underlying mechanisms as  
proof-of-principal. Studies of risk factors associated with human autoimmune disease may provide 
hints as to what exposure types and doses to evaluate in animal models. There are reasonably good  
in vitro data for some exposures (e.g., mercury) where the exposures achieved following animal  
dosing in vivo may be comparable to levels found in humans [76]. Other relevant associations  
seen in experimental studies may include EBV associated with MS, mineral oil components with 
RA/SLE/inflammatory arthritis. 
Further research was recommended to explore similarities and differences between animal models 
and humans in the metabolism, pharmacokinetics, distribution/internal dose, and target organ dose of 
specific xenobiotics related to autoimmunity. Given the current limitations of exposure assessment in 
human studies, efforts are needed to determine the validity of biomarkers of exposure, for example 
methylation arrays and self-protein reactivity arrays to citrullinated or glycosylated proteins. 
Topic 3—How do susceptible populations, time frames of exposure, or genetic predisposition 
contribute to exposure-related autoimmune disease?  
Many intrinsic factors (e.g., genetics, gender, age) work together in complex ways to contribute to 
the development of exposure-related autoimmune disease; these interactions are likely to be both 
complex within given exposure/disease relationships and variable across different types of exposures 
and diseases. Animal models provide examples of differences in autoimmune susceptibility by age or 
genetic background (e.g., mercury [77]). Human studies also provide proof of principle—for example 
the difference in relationship between smoking, autoantibodies and RA phenotypes depending on the 
human leukocyte antigen (HLA)-DR4. Animal models suggest the time frame of exposure is likely to 
be important, for example prenatal/early life TCDD exposures may have different outcomes than 
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exposures more proximal to autoimmune onset [78,79]. Confirmation is needed in humans that 
exposure timing (e.g., early life exposures versus later life exposures) affects disease risk, which may 
be difficult given the long latency time and challenges in assessing early life exposures. Other 
examples that timing or genetic factors are likely to be important include the timing of the introduction 
of complex foods during infancy and T1D, and UV exposure interacting with genetic risk factors in 
MS risk [16]. 
The interactions of age, gender, genetics and windows/timeframes with environmental exposure(s), 
and the impact of their relative contributions, are critical to a more complete understanding of the 
development of autoimmune diseases. Recommendations for further investigation included: mechanisms 
underlying sex or gender differences in autoimmune-effects of solvents and other environmental 
exposures, and timing of exposures and role of genetic susceptibility for several exposures, including 
sunlight (e.g., protection against MS), vitamin D, silica, and EBV infection. Findings on genetic 
susceptibility in human autoimmune diseases, e.g., HLA-DR4 and RA, should be incorporated into 
animal models (e.g., humanized mice) when possible. 
Topic 4—To what extent does ability to quantify environmental exposures limit our ability to identify 
factors associated with human autoimmune disease?  
Limitations in methods and technologies to assess environmental exposures in humans can 
substantially hinder the detection of exposures related to the development of autoimmune disease. 
Better exposure data would produce more accurate dose-response estimates and lead to identification 
of more risk factors. For example, using a less sensitive and specific method for silica exposure made  
a substantial difference in observed association with lupus [66]. Because autoimmune diseases in 
humans are relatively uncommon, case-control studies are often needed to achieve sufficient numbers 
of cases for analyses. Thus, there is a particular need for the development and dissemination of 
methods to assess historical exposures. 
The low incidence of many of the individual diseases (especially in men) presents a logistical 
challenge for studies in exposure-enriched populations, e.g., occupational cohorts, which often have 
higher levels of specific exposures and sometimes also include measurement data. Likewise the rarity 
of some exposures (e.g., high level silica exposure) present challenges in studies conducted in the 
general population or patient registries. 
There is an urgent need to develop cost-effective non-invasive methods to quantify those 
environmental exposures most likely related to autoimmune disease in both human populations  
and animal models. New technologies must be developed, and emerging technologies exploited. 
Recommendations were provided in the context of the panel discussion specifically devoted to the 
topic of exposure assessment (above). 
Topic 5—How well do mechanistic studies in vivo or in vitro relate to clinical outcomes?  
There is a paucity of studies that relate autoimmune disease mechanisms with clinical measures  
and exposure-associated autoimmune diseases. It was generally agreed that experimental/mechanistic 
studies are focused on models used for proof of principle, and so findings do not correspond well with 
what is known in humans. Table 4 reviews knowledge on mechanisms related to three exposures 
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identified with the greatest confidence as being associated with human disease in this workshop: 
smoking, silica, and solvents. 
One of the most solid examples is the mechanistic relationship between citrullination, a form of 
post-translational modification and the development of autoantibodies to citrullinated proteins, thought 
to suggest a causal role for smoking in the development of RA [80]. Experimental data is somewhat 
limited, however studies of gene-environment interactions and other human studies are providing 
additional clues to etiologic pathways [81–83]. The role of other smoking-related mechanisms in RA 
including heat shock gene expression and related autoantibodies is less clear [84,85]. Notably, animal 
models suggest nicotine-associated delays in development of arthritis [86,87]. 
Despite the strong and consistent associations of silica with multiple systemic autoimmune diseases, 
there relatively little evidence on the possible mechanisms underlying this relationship. Silica exposure 
can exacerbate lupus in rodent models [88]; though the mechanisms by which this occurs are not 
established, hypotheses include an adjuvant effect. Other evidence coming from human studies includes 
associations of silica exposure with dysregulation of apoptosis and balances of T-helper/Treg [89,90], 
and associations of silica disease-specific autoantibodies in a highly exposed population [91]. 
Lastly, although the solvent/SSc association seen in human studies is consistent, it lacks support 
from specific animal models of SSc. However, indirect evidence comes from the observed specificity 
of the solvent association in patients with disease-specific autoantibodies [92]. By contrast, a large 
body of literature provides evidence of one specific solvent, Trichloroethylene, in immune disease 
regulation, such as increased IFN-γ and decreased IL-4, and disease aggravation/acceleration in  
lupus models [93]. 
Table 4. Evidence and hypothesized mechanisms underlying autoimmune disease 
associations with smoking, silica, and solvents.  
Exposure-Disease Association in Humans Evidence on in Vitro and in Vivo Mechanisms 
Smoking and seropositive-RA 
Post-translational modification—antigen citrullination and  
anti-cyclic citrullinated peptides (CCP) antibodies [80,82];  
Nicotine and Th17 activation [86,87];  
Upregulation of heat shock gene expression [84] *;  
Disease relevant autoantibodies (RF, anti-HSP70) [85] *. 
Silica and RA/SLE/SSc/ 
ANCA-vasculitis 
Aggravation of lupus in animal models [88];  
Adjuvant effect-apoptotic debris [88];  
Dysregulation of apoptosis [90] *;  
Disease relevant autoantibodies (anti-dsDNA, anti-Ro/SSA, 
anti-La/SSB antibodies in silica associated SLE) [91] *;  
Altered CD4+/CD4+ CD25+ T cell ratio [89] *. 
Solvents and SSc 
Accelerated autoimmunity in animal models [93]  
SSc disease relevant autoantibodies (anti-Scl-70) [92]  
Increased IFN-γ, reduced IL-4 [93] * 
* Similar observations made in animal studies. 
Patterns of T and B cell skewing, antibody and cytokine profiling may be useful biomarkers of 
autoimmune disease or predisposition, and represent mechanisms linking the environment with  
disease initiation. Data in human studies on autoantibody profiles in patients, controls and high-risk 
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populations would allow examine exposure-associations with specific autoantibodies and whether 
exposures impact development or progression of disease susceptible populations (e.g., due to genetic 
or autoantibody profiles). Many models have been established to study mechanisms regulating 
autoimmune diseases, and these need to be tested in terms of their role in exposure-mediated disease. 
Inclusion of more mechanistic endpoints in human autoimmune studies will entail important  
logistical adjustments. The collection of patient samples must provide access to live cells for in vitro 
investigations, e.g., preserving peripheral mononuclear blood cells rather than merely serum samples for 
future functional assays and phenotyping. This will require greater collaboration and understanding 
between basic environmental health scientists, autoimmune clinicians, and environmental epidemiologists. 
Topic 6—How well do in vitro mechanisms relate to in vivo mechanisms in animals or effects of 
human exposures?  
There is a growing list of examples (e.g., Hg and silica) showing concordance between mechanistic 
findings from in vitro and in vivo studies in laboratory animals. The types of mechanisms for which 
there is agreement include: apoptosis, co-stimulation, antigen clearance and presentation, cytokines 
and signaling. In most model systems there is good correlation between in vitro and in vivo outcomes, 
for example AhR modulation [94,95]. At the same time, in vitro systems are often too limited to 
recapitulate observations from animal models.  
At the same time, there is inadequate data on whether most exposure-related autoimmune 
mechanisms are found in humans at relevant exposure levels, though there are some suggestive  
data regarding cytokines, lymphocyte subsets, DNA methylation and other epigenetic factors, e.g., for 
silica and air pollution [90,96–98]. Oxidative stress, specific environmental chemical receptors, and 
environmentally-induced TLR activation likely play a role in development of human disease [20,99]. 
While in vitro evidence suggests AhR ligands can affect T cell differentiation [34,100,101], additional 
animal in vivo and human studies are needed to determine the importance of these findings. Analyses 
of different molecular and biological outcomes following AhR activation with different classes of 
ligands (e.g., dioxins, PCBs, dietary flavonoids) should also be pursued as a model for context-specific 
environmental chemical signaling. 
3. Summary and Conclusions 
3.1. Overall Advances in this Field 
Critical advances in the field of autoimmune disease research include a growing understanding of 
the contribution of antigen specific T cell subsets, B cell antibody repertoire, and antigen presentation. 
Specific to the role of environmental factors in autoimmune disease etiology, there has been an 
improved understanding of the role of specific signaling molecules (e.g., TLRs, AhR). Other advances 
include the emergence of new technologies for assessing molecular markers (e.g., gene, methylation, 
and antibody arrays), genetic manipulations in animal models to define mechanisms and potential  
use of the GWAS (genome-wide association studies) repository. A key finding from human studies 
includes the identification an environmental exposure (cigarette smoke), which interacts with genetic 
factors to promote specific RA phenotypes and for which there are relevant mechanistic data, which 
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provides a model for future studies of environmental autoimmunity integrating exposure, genotype, 
and phenotype. 
3.2. Conclusions and Recommendations 
More “translational” epidemiological studies of environmental autoimmunity are needed and should 
be guided by mechanisms defined in model systems and vice versa. An integrated, multidisciplinary 
approach is critical, and programs should be established to provide opportunities for collaboration and 
improve communication between epidemiologists, exposure scientists, and basic cellular/molecular 
biologists, i.e., fostering of interdisciplinary research through forums, funding and training. Funding 
opportunities need to be specifically targeted towards autoimmunity and environmental factors. Better 
coordination across the diverse disciplines and agencies conducting autoimmune research may help  
to encourage collaborations. Such coordinated efforts may also promote a more cohesive body of 
knowledge through studies of multiple autoimmune diseases with similar underlying mechanisms, and 
shared genetic or environmental risk factors. 
An important need for human autoimmune research is the availability of high-quality,  
validated measurement tools. Similar to efforts to characterize the genome, new technologies should 
be harnessed to address the critical need to characterize human environmental exposures.  
An environment-wide association (i.e., “exposome”) database linked to common questionnaires would 
facilitate epidemiological studies. More data are also needed on the contribution of psychosocial 
factors, infections, complex mixtures and susceptibility factors to the development of autoimmune 
diseases. Biomarkers identified by mechanistic studies should be applied to epidemiologic research in 
the context of relevant exposure measures. Investments in high quality exposure measures and biological 
markers will increase the ability to identify environmental contributions to the etiopathogenesis of 
autoimmune diseases. 
Finally, a consensus-based approach should be developed to define autoimmune phenotypes  
(rather than diseases), which may improve comparability between human studies and animal models. 
The focus on studying diseases defined by classification criteria may limit interpretation of animal 
model data and the ability to identify human exposure cohorts using the broadest disease definitions. 
Conversely, there is a need for animal models to better represent phenotypes that occur in human 
diseases (e.g., CNS-lupus). Some environmental exposures may cause diseases characterized by a 
mixture of outcomes or multiple phenotypes that do not fit standard diagnostic criteria. Outbreak 
investigations should collect data to characterize the emerging phenotypes, and include the 
preservation and archiving of biological specimens. Long-term follow-up of affected individuals is 
critical to assess phenotypes that might develop with long latency. 
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